REYATAZ
REYATAZ Brand names, REYATAZ Analogs
REYATAZ Brand Names Mixture
- No information avaliable
REYATAZ Chemical_Formula
C38H52N6O7
REYATAZ RX_link
http://www.rxlist.com/cgi/generic3/reyataz.htm
REYATAZ fda sheet
REYATAZ msds (material safety sheet)
REYATAZ Synthesis Reference
No information avaliable
REYATAZ Molecular Weight
704.856 g/mol
REYATAZ Melting Point
No information avaliable
REYATAZ H2O Solubility
Free base slightly soluble (4-5 mg/mL)
REYATAZ State
Solid
REYATAZ LogP
4.25
REYATAZ Dosage Forms
Capsule (100 mg, 150 mg, or 200 mg)
REYATAZ Indication
For use, in combination with other antiretroviral agents, in the treatment of HIV-1 infection.
REYATAZ Pharmacology
Atazanavir (ATV) is an azapeptide HIV-1 protease inhibitor (PI). It is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Protease inhibitors block the part of HIV called protease. HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Atazanavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs.
REYATAZ Absorption
Atazanavir is rapidly absorbed with a Tmax of approximately 2.5 hours. Administration of atazanavir with food enhances bioavailability and reduces pharmacokinetic variability
REYATAZ side effects and Toxicity
No information avaliable
REYATAZ Patient Information
REYATAZ Organisms Affected
Human immunodeficiency virus
